+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 65Years
All Genders
ID07412704

Open-label Study Evaluating Safety, Pharmacokinetics, and Effects of BMS-986528 in Adults With Difficult-to-Treat Rheumatoid Arthritis

Led by Bristol-Myers Squibb · Updated on 2026-10-23

84

Participants Needed

39

Research Sites

43 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety, tolerability, how the body processes, and potential disease-modifying effects of a drug called BMS-986528 in adults with refractory, difficult-to-treat rheumatoid arthritis RA. This early-phase trial aims to gather initial data on the drugs impact in this group of patients. The study is sponsored by Bristol-Myers Squibb and focuses on participants aged 18 to 65 with this challenging form of RA. Participants receive specified doses of BMS-986528 on certain days during the trial. The study includes multiple experimental cohorts, each receiving the drug under close monitoring. Throughout the treatment period, various measurements are taken to assess how the drug behaves in the body, including concentrations and clearance, as well as its effects on immune cells and antibody levels. During the study, participants are regularly assessed for any treatment-emergent side effects and serious adverse events up to week 54. Researchers also evaluate changes in disease activity scores and immune system markers. These evaluations involve blood tests and clinical assessments to monitor safety and potential benefits. The entire participation period extends up to approximately 54 weeks, allowing for comprehensive observation.

CONDITIONS

Brief Title

A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

Research Team

B

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

F

First line of the email MUST contain NCT # and Site #.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here